Article thumbnail

Disruption of Learning Processes by Chemotherapeutic Agents in Childhood Survivors of Acute Lymphoblastic Leukemia and Preclinical Models

By Emily B. Bisen-Hersh, Philip N. Hineline and Ellen A. Walker

Abstract

Objective: With the survival rate of acute lymphoblastic leukemia (ALL) surpassing 90 percent within this decade, new research is emerging in the field of late effects. A review of the research investigating the relationship of treatment regimens for ALL to specific late effect deficits, underlying mechanisms, and possible remediation is warranted to support continued studies

Topics: Review
Publisher: Ivyspring International Publisher
OAI identifier: oai:pubmedcentral.nih.gov:3100681
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1985). A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults.
  2. (2007). A meta-analysis of the neurocognitve sequelae of treatment for childhood acute lymphocytic leukemia. Pediatr Blood Cancer.
  3. (1986). A model of methotrexate encephalopathy: neurotransmitter and pathologic abnormalities.
  4. (1991). A prospective comparison of neuropsychologic performance of children surviving leuke-Journal of Cancer 2011, 2 http://www.jcancer.org mia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol.
  5. (2000). Academic career after treatment for acute lymphoblastic leukaemia. Arch Dis Child.
  6. (2007). Acute neurocognitive response to methylphenidate among survivors of childhood cancer: a randomized, double-blind, cross-over trial. J Pediatr Psychol.
  7. (1983). An animal model to detect learning deficits following treatment of the immature brain. Child‘s Brain.
  8. (1989). An animal model to detect the neuropsychological toxicity of anticancer agents. Med Pediatr Oncol.
  9. (2000). and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsych.
  10. (2010). Animal Models. In:
  11. (2003). Assessment of developmental milestones in rodents. Curr Protoc Neurosci.
  12. (2003). Assessment of sustained and divided attention in rats. Curr Protoc Neurosci.
  13. (1994). Association of 1800 cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. Lancet.
  14. (2005). Attention and information processing in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. Pediatr Blood Cancer.
  15. (2010). Attention and working memory abilities in children treated for acute lymphoblastic leukemia.
  16. (1999). Attentional ability among survivors of leukaemia. Arch Dis Child.
  17. (2008). Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the venice cognitive workshop. Ann Oncol.
  18. (2007). Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res.
  19. (2007). Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer.
  20. (1998). Central action of some cytostatics—methotrexate (MTX) and doxorubicin (DXR): II. The influence on the seizure activity and the learning and memory processes in mice. Ann Univ Mariae Curie Sklodowska.
  21. (2001). Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. J Pediatr Psychol.
  22. (2005). Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer.
  23. (1992). Chemotherapy for acute lymphocytic leukemia: cognitive and academic
  24. Children‘s Oncology Group. Establishing and enhancing services for childhood cancer survivors: long-term follow-up program resource guide. http://www.survivorshipguidelines.org/
  25. (2006). Chronic health conditions in adult survivors of childhood cancer.
  26. (2002). CNS late-effects after ALL therapy in childhood. Part III: Neuropsychological performance in long-term survivors of childhood ALL: impairments of concentration, attention, and memory. Med Pediatr Oncol.
  27. (2006). CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in
  28. (1991). CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsychological, and behavioral effects? Neuropsychol Rev.
  29. (2008). Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis.
  30. (1990). Cognitive functioning in long-term survivors of childhood leukemia: a prospective analysis. J Dev Behav Pediatr.
  31. (2000). Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol.
  32. (1995). Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice.
  33. (2006). Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate. J Clin Oncol.
  34. (2009). Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia. J Clin Oncol.
  35. (2008). Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulate cortex of rats. Brain Res Bull.
  36. (2003). Developmental model relating white matter volume to neurocognitive deficits in pediatric brain tumor survivors.
  37. (2009). Differential effects of paclitaxel treatment on cognitive functioning and mechanical sensitivity. Neurosci Lett.
  38. (1994). Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia.
  39. (2004). Effect of chronic vincristine treatment on mechanical withdrawal response and pre-pulse inhibition in the rat. Neurosci Lett.
  40. (2008). Effects of chemotherapeutic agents 5-fluorouracil and methotrexate alone and combined in a mouse model of learning and
  41. (2009). Effects of chemotherapy on neurocognitive function in children with acute lymphoblastic leukemia: a critical review of the literature. Pediatr Blood and Cancer.
  42. (2010). Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. Behav Brain Res.
  43. (2011). Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by methotrexate chemotherapy. Psychopharmacology.
  44. (2002). Hippocampal brain amines in methotrexate-induced learning and memory deficit.
  45. (2010). IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice. Cancer Invest.
  46. (2010). Impact of acute lymphoblastic leukemia therapy on attention and working memory in children. Expert Rev Hematol.
  47. (2010). Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. Brain Res Bull.
  48. (1994). Interactions of steroid, methotrexate, and radiation determine neurotoxicity in an animal model to study therapy for childhood leukemia. Pediatr Res.
  49. (2006). Is ‗chemo-fog‘/‘chemo-brain‘ caused by cancer chemotherapy? J Clin Pharm Ther.
  50. (2000). Late effects of survivors of infant leukemia.
  51. (1998). Late sequelae of CNS recurrence of acute lymphoblastic leukemia in childhood. Klin Padiatr.
  52. (2006). Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the childhood cancer survivor study. J Clin Oncol.
  53. (2008). Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res.
  54. (1999). Long-term effects of cranial radiation therapy on attentional functioning in survivors of childhood leukemia. J Pediatr Psychol.
  55. (1992). Long-term neuropsychologic sequelae of childhood leukemia: comparison of two CNS prophylactic regimens. Int J Radiat Oncol.
  56. (1995). Methotrexate does not interfere with an appetitive pavlovian conditioning task in sprague-dawley rats. Physiol Behav.
  57. (2010). Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res.
  58. (1999). MRI morphometry of mamillary bodies, caudate nuclei, and prefrontal cortices after chemotherapy for childhood leukemia: multivariate models of early and late developing memory subsystems. Behav Neurosci.
  59. (2011). Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev.
  60. (2006). Neurocognitive effects of treatment for childhood cancer. Ment Retard Dev Dis Rev.
  61. Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.
  62. (2004). Neurocognitive sequelae of childhood cancers and their treatment. Pediatr Rehabilitation.
  63. (2008). Neurodevelopmental sequelae of pediatric acute lymphoblastic leukemia and its treatment. Dev Dis Rev.
  64. (1989). Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol.
  65. (2008). Pathway genetic polymorphisms are related to attention disorders in childhood leukemia survivors. J Pediatr.
  66. (2009). Pediatric cancer survivorship research: experience of the childhood cancer survivor study. J Clin Oncol.
  67. (1987). Post irradiation treatment outcomes for children with acute lymphocytic leukemia. J Pediatr Psychol.
  68. (2010). Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial. J Pediatr Psychol.
  69. (2000). Processing speed, working memory, and IQ: a developmental model of cognitive deficits following cranial radiation therapy. Neuropsychology.
  70. (2008). Reliability and validity of the childhood cancer survivor study neurocognitive questionnaire.
  71. (2003). Risk-taking behavior in adolescent mice: psychobiological determinants and early epigenetic influence. Neurosci Biobehav Rev.
  72. (2008). Screening for neurocognitive impairment in pediatric cancer long-term survivors. J Clin Oncol.
  73. (2009). Sex-specific attention problems in long-term survivors of pediatric acute lymphoblastic leukemia.
  74. (1999). Spatial learning deficits in rats after injection of vincristine into the dorsal hippocampus. Neuroscience.
  75. (2009). Systemic administration of doxorubicin impairs aversively motivated memory in rats. Pharmacol Biochem Behav.
  76. (2002). Tamoxifen and toremifene cause impairment of learning and memory function in mice. Pharmacol Biochem Behav.
  77. (1998). The behavioral neurology of cerebral white matter.
  78. (2010). The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Behav Brain Res.
  79. (1989). The effect of methotrexate on the development of synapses in the neonatal rat hippocampus. Neuropediatrics.
  80. (2006). The effects of anti-cancer drugs, methotrexate and 5-fluorouracil on cognitive function in mice. Pharmacol Biochem Behav.
  81. (1981). The effects of prophylactic treatment of the central nervous system on the intellectual functioning of children with acute lymphocytic leukemia.
  82. (1992). The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol.
  83. (2006). Treatment of acute lymphoblastic leukemia.
  84. (2009). Treatment of childhood acute lymphoblastic leukemia without prophylactic cranial irradiation.
  85. (1986). Treatment-related white matter changes in cancer patients.
  86. (2008). Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia.
  87. (1998). Unilateral hippocampal lesions in newborn and adult rats: effects on spatial memory and BDNF gene expression. Behav Brain Res.
  88. (2004). Visual attention in long-term survivors of leukemia receiving cranial radiation therapy.